Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3129

Rhythm touts Phase 3 win for rare obesity drug in people with brain damage

$
0
0
Rhythm Pharmaceuticals is looking to expand the potential market for its rare obesity treatment Imcivree beyond genetic disorders. The company said Monday the medicine reduced body weight in a late-stage trial of people with obesity ...

Viewing all articles
Browse latest Browse all 3129

Trending Articles